Type your tag names separated by a space and hit enter

Acetylcholinesterase inhibitors for schizophrenia

Evidence Summaries

Level of Evidence = D

Acetylcholinesterase inhibitors in combination with antipsychotics might possibly be effective on a few domains of mental state and cognition in patients with schizophrenia, although the evidence is insufficient.

A Cochrane review 1 included 17 studies with a total of 670 subjects. Nine trials included people with a sole diagnosis of schizophrenia, 7 studies with a diagnosis of schizophrenia or schizoaffective disorder and one study with no clear diagnostic criteria. The most commonly used acetylcholinesterase inhibitors were donepezil, rivastigmine and galantamine. The overall rate of participants leaving studies early was low (13.6 %) and showed no clear difference between the two groups. The primary outcome of interest was reported in only five studies. The acetylcholinesterase inhibitor plus antipsychotic showed benefit over antipsychotic and placebo in the following outcomes. 1. Mental state - PANSS negative symptoms average end point score (MD -1.69 95% CI -2.80 to -0.57; 2 RCTs, n = 31) and PANSS General Psychopathology average end point score (MD -3.86 95% CI -5.40 to -2.32; 2 RCTs, n = 31). 2. Cognitive domains - attention, (MD 1.20 95% CI 0.14 to 2.26; 1 RCT, n = 73), visual memory (MD 1.90 95% CI 0.52 to 3.28; 2 RCTs, n = 48), verbal memory and language (MD 3.46 95% CI 0.67 to 6.26; 3 RCTs, n = 42) and executive functioning (MD 17.10 95% CI 0.70 to 33.50; 1 RCT, n = 24). 3. Tolerability - EPSE: AIMS, (MD 1.50 95% CI 1.04 to 1.96; 1 RCT, n = 35). No difference was noted between the two arms in other outcomes.

Comment: The quality of the evidence is downgraded by study quality (inadequate allocation concealment, lack of blinding, short follow-up), imprecise results (limited study size for each comparison) and indirectness of evidence (differences in studied outcomes).


1. Singh J, Kour K, Jayaram MB. Acetylcholinesterase inhibitors for schizophrenia. Cochrane Database Syst Rev 2012;1:CD007967.  [PMID:22258978]

Copyright © 2017 Duodecim Medical Publications Limited.
Acetylcholinesterase inhibitors for schizophrenia is a sample topic from the Evidence-Based Medicine Guidelines.

To view other topics, please or purchase a subscription.

Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Learn more.


"Acetylcholinesterase Inhibitors for Schizophrenia." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/457420/all/Acetylcholinesterase_inhibitors_for_schizophrenia.
Acetylcholinesterase inhibitors for schizophrenia. Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. https://evidence.unboundmedicine.com/evidence/view/EBMG/457420/all/Acetylcholinesterase_inhibitors_for_schizophrenia. Accessed March 24, 2019.
Acetylcholinesterase inhibitors for schizophrenia. (2019). In Evidence-Based Medicine Guidelines. Available from https://evidence.unboundmedicine.com/evidence/view/EBMG/457420/all/Acetylcholinesterase_inhibitors_for_schizophrenia
Acetylcholinesterase Inhibitors for Schizophrenia [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. [cited 2019 March 24]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/457420/all/Acetylcholinesterase_inhibitors_for_schizophrenia.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - Acetylcholinesterase inhibitors for schizophrenia ID - 457420 BT - Evidence-Based Medicine Guidelines UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/457420/all/Acetylcholinesterase_inhibitors_for_schizophrenia PB - Duodecim Medical Publications Limited DB - Evidence Central DP - Unbound Medicine ER -